a measure of how credible it is...by contrast, the "New England Journal of Medicine" NEJM's IF is 74.699...in point of fact, the AJM doesn't make the Top 20 journals...here is what the NEJM had to say about HCQ...(dated Nov. 19, 2020...long after Dr. Risch's claims were made.
-------------------
Abstract
BACKGROUND
Hydroxychloroquine and chloroquine have been proposed as treatments for coronavirus disease 2019 (Covid-19) on the basis of in vitro activity and data from uncontrolled studies and small, randomized trials.
METHODS
In this randomized, controlled, open-label platform trial comparing a range of possible treatments with usual care in patients hospitalized with Covid-19, we randomly assigned 1561 patients to receive hydroxychloroquine and 3155 to receive usual care. The primary outcome was 28-day mortality.
RESULTS
The enrollment of patients in the hydroxychloroquine group was closed on June 5, 2020, after an interim analysis determined that there was a lack of efficacy. Death within 28 days occurred in 421 patients (27.0%) in the hydroxychloroquine group and in 790 (25.0%) in the usual-care group (rate ratio, 1.09; 95% confidence interval [CI], 0.97 to 1.23; P=0.15). Consistent results were seen in all prespecified subgroups of patients. The results suggest that patients in the hydroxychloroquine group were less likely to be discharged from the hospital alive within 28 days than those in the usual-care group (59.6% vs. 62.9%; rate ratio, 0.90; 95% CI, 0.83 to 0.98). Among the patients who were not undergoing mechanical ventilation at baseline, those in the hydroxychloroquine group had a higher frequency of invasive mechanical ventilation or death (30.7% vs. 26.9%; risk ratio, 1.14; 95% CI, 1.03 to 1.27). There was a small numerical excess of cardiac deaths (0.4 percentage points) but no difference in the incidence of new major cardiac arrhythmia among the patients who received hydroxychloroquine.
CONCLUSIONS
Among patients hospitalized with Covid-19, those who received hydroxychloroquine did not have a lower incidence of death at 28 days than those who received usual care. (Funded by UK Research and Innovation and National Institute for Health Research and others; RECOVERY ISRCTN number, ISRCTN50189673. opens in new tab; ClinicalTrials.gov number, NCT04381936. opens in new tab.
------------------------
I do know how to read...as well as judge where to get the best information...also, if I have a question on a subject like HCQ, I have a family member who is a certified expert in the field of Infectious Diseases and who I can go to with questions...(Baron is not certified in ID)...I did ask about HCQ and was given this response..."Hydroxychloroquine is totally debunked. Not helpful and is literally a joke in the ID community."
This is another example of Baron being frustrated by the fact that someone else can always have the upper hand in any discussion regarding COVID-19, and probably goes a long way toward explaining why he chose to "Ignore" me...too bad, Baron...you need to face reality...
Link: https://www.kolabtree.com/blog/top-20-medical-journals-for-physicians-to-publish-in/
